Gemigliptin市場：按藥物類型、按配銷通路、按最終用戶、按患者人口統計、按地區

Gemigliptin Market, By Type of Drug, By Distribution Channel, By End User, By Patient Demographics, By Geography

出版日期: 2023年12月12日 | 出版商:

Coherent Market Insights | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023年全球Gemigliptin市場規模為17.9億美元，預計2030年將達25.9億美元，2023年至2030年年複合成長率為5.4%。

報告範圍		報告詳情
基準年	2022年	2023年市場規模	17.9億美元
實際資料	2018-2021	預測期	2023-2030
預測期年複合成長率	5.40%	2030年市場規模預測	25.9億美元

圖 1. Gemigliptin全球市場佔有率（%），依地區分類，2023年

Gemigliptin 是一種有效的選擇性Dipeptidyl Peptidase-4（DPP-4）抑制劑，用於治療第2 型糖尿病。由於其獨特的化學結構，它通過增強腸促胰島素激素的作用來有效降低血糖值。這種口服藥物透過促進葡萄糖依賴性胰島素分泌和抑制升糖素釋放而在血糖控制方面具有良好的效果。Gemigliptin（DPP-4 抑制劑類新藥）的安全性和有效性使其成為尋求改善血糖控制和降低低血糖風險的糖尿病患者的寶貴選擇。該藥物獨特的化學結構和作用機制使其有別於其他抗糖尿病藥物。Gemigliptin通常每日一次口服治療，為糖尿病患者提供便利。然而，進行的研究、策略行銷以及配方和聯合治療的潛在創新目的是將Gemigliptin定位為各種糖尿病管理環境中的有價值的選擇。

市場動態：

糖尿病盛行率的上升、糖尿病意識和診斷的提高以及向口服抗糖尿病藥物的轉變預計將在預測期內推動全球Gemigliptin市場的成長。此外，有利的法規環境預計也將推動預測期內全球Gemigliptin市場的成長。新興市場的擴張、聯合治療、致力於以患者為中心的方法、兒童使用、妊娠糖尿病等預計將為預測期內的全球Gemigliptin市場提供成長機會。

然而，與現有藥物的競爭、專利到期、學名藥藥競爭和安全性擔憂預計將阻礙預測期內Gemigliptin市場的成長。

本研究的主要特點

本報告對Gemigliptin市場進行了詳細分析，並提供了以2022年為基準年的預測期（2023-2030）的市場規模和年複合成長率（CAGR%）。
揭示了各個細分市場的潛在商機，並為該市場說明了一系列有吸引力的投資提案。
提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的主要考察。
根據公司亮點、產品系列、主要亮點、財務表現和策略等參數來介紹Gemigliptin市場的主要企業。
本報告的見解使行銷人員和公司負責人能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。
Gemigliptin市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
透過用於分析Gemigliptin市場的各種策略矩陣，將促進相關人員的決策。

Report Coverage	Report Details
Base Year:	2022	Market Size in 2023:	US$ 1.79 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	5.40%	2030 Value Projection:	US$ 2.59 Bn

Gemigliptin is a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor used in the management of type 2 diabetes mellitus. With its unique chemical structure, gemigliptin effectively lowers blood glucose levels by enhancing the action of incretin hormones. This oral medication offers promising results in gycemic control by promoting glucose-dependent insulin secretion and suppressing glucagon release. As a newer entrant in the DPP-4 inhibitor class, Gemigliptin's safety profile and efficacy make it a valuable option for diabetes patients seeking improved glucose regulation and a reduced risk of hypoglycaemia. This medication is characterized by its unique chemical structure and mechanism of action, setting it apart from other antidiabetic drugs. Gemigliptin is typically prescribed as a once-daily oral treatment, providing convenience for patients managing their diabetes. However, ongoing research, strategic marketing, and potential innovations in formulation or combination therapies aim to position gemigliptin as a valuable option in the diverse landscape of diabetes management.

Market Dynamics:

The rising prevalence of diabetes, increasing awareness and diagnosis, and shift towards oral antidiabetic drugs are anticipated to drive growth of the global gemigliptin market over the forecast period. Moreover, a favorable regulatory environment is also expected to boost the growth of the global gemigliptin market over the forecast period. Expansion in emerging markets, combination therapies, a focus on patient-centric approaches, pediatric use, and gestational diabetes are expected to create growth opportunities for the global gemigliptin market during the forecast period.

However, competition from established drugs, patent expiry, generic competition, and safety concerns are expected to hamper growth of the gemigliptin market over the forecast period.

Key features of the study:

This report provides in-depth analysis of the gemigliptin market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the gemigliptin market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Daewoong Pharmaceutical, Sanofi, LG Chem, Hanmi Pharmaceutical Co., Ltd., and Merck
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The gemigliptin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the gemigliptin market

Detailed Segmentation:

Gemigliptin Market Segmentation, By Type of Drug:
- Gemigliptin Monotherapy
- Gemigliptin Combination Therapy
Gemigliptin Market Segmentation, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Gemigliptin Market Segmentation, By End User:
- Hospitals
- Clinics and Outpatient Facilities
- Others (Academic and Research Institutes)
Gemigliptin Market Segmentation, By Patient Demographics:
- Adult Population
- Geriatric Population
Gemigliptin Market Segmentation, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profile:
- Daewoong Pharmaceutical
- Sanofi
- LG Chem
- Hanmi Pharmaceutical Co., Ltd.
- Merck

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Gemigliptin , By Type of Drug
- Market Gemigliptin , By Distribution Channel
- Market Gemigliptin , By End User
- Market Gemigliptin , By Patient Demographics
- Market Gemigliptin , By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
Rising prevalence of diabetes
- Restraints
Competition from established drugs
- Opportunities
Expansion in emerging markets
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Gemigliptin Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Gemigliptin Market , By Type of Drug, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Gemigliptin Monotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Gemigliptin Combination Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

6. Gemigliptin Market , By Distribution Channel, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

7. Gemigliptin Market , By End User, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Retail Clinics and Outpatient Facilities
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Others (Academic and Research Institutes)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

8. Gemigliptin Market , By Patient Demographics, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Adult Population
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Geriatric Population
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

9. Gemigliptin Market , By Region, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, By Country, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Country 2019-2030
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Drug, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Denographics, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Drug, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Denographics, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Drug, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Denographics, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Drug, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Denographics, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Drug, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Denographics, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Drug, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Denographics, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2018-2030, (US$ Bn)
North Africa
Central Africa
South Africa

10. Competitive Landscape

Daewoong Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
LG Chem
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Hanmi Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Merck
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Analyst Views